Ipsen commits about $1B to acquire Simcere’s China preclinical ADC program
Ipsen is investing roughly $1 billion to secure Simcere's China-based preclinical ADC program, aiming to accelerate oncology R&D and expand its commercial footprint in Asia.
Yahoo Finance
2 min read
Pharmaceuticals
Biotech
Market Analysis